A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

BACKGROUND: In type 2 diabetes mellitus, fixed-dose combination (FDC) can provide the complementary benefits of correction of multiple pathophysiologic defects such as dysfunctions in glycemic or metabolic control while improving compliance compared with separate tablets taken together. The objectiv...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Drug Des Devel Ther
Egile Nagusiak: Park, Sang-In, Lee, Howard, Oh, Jaeseong, Lim, Kyoung Soo, Jang, In-Jin, Kim, Jeong-Ae, Jung, Jong Hyuk, Yu, Kyung-Sang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324327/
https://ncbi.nlm.nih.gov/pubmed/25678778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S75980
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak